Oct 13 (Reuters) - Glaxosmithkline Plc GSK.L :
* SHINGRIX HAS BEEN APPROVED IN CANADA FOR PREVENTION OF SHINGLES (HERPES ZOSTER) IN PEOPLE AGED 50 YEARS OR OLDER
* APPROVAL IN CANADA WAS BASED ON PHASE III CLINICAL TRIAL PROGRAMME EVALUATING ITS EFFICACY, SAFETY AND IMMUNOGENICITY IN MORE THAN 37,000 PEOPLE